

Advances in Malignant Lymphoma: From Discovery to Clinical Impact

in cooperation with the International Conference on Malignant Lymphoma (ICML)
June 24-27, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

CHAIR

Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

COCHAIRS

Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland*

Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX

Jean L. Koff, Winship Cancer Institute of Emory University, Atlanta, GA

Ari M. Melnick, Josep Carreras Leukaemia Research Institute, Barcelona, Spain

Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY

Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA

* - ICML Representative

Wednesday, June 24

Registration

1-8 p.m. | Grand Ballroom Foyer

Welcome and Keynote Address

5-6 p.m. | Grand Ballroom ABC

5 p.m. Welcome and Introduction of Keynote Speaker

Michael Green, The University of Texas MD Anderson Cancer Center, Houston, TX

5:10 p.m. Opening Keynote Lecture

Ron Levy, Stanford University, Stanford, California

Plenary Session 1: Antibodies through the eras

6-7:50 p.m. | Grand Ballroom ABC

Session Chair: Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas

6-6:30 Monoclonal Antibodies for Lymphoma

Dave Maloney Fred Hutch Seattle, Washington

6:30-7 Clinical challenges and developments for antibody drug conjugates and bispecific antibodies / T-cell engagers

Gilles Salles, Memorial Sloan King Cancer Center, New York, New York

7-7:30 Bispecific antibodies in B-cell lymphomas: Redefining immune engagement in the therapeutic landscape

Elicia Penuel, Genentech/Roche, San Francisco, California

Advances in Malignant Lymphoma: From Discovery to Clinical Impact

in cooperation with the International Conference on Malignant Lymphoma (ICML)
June 24-27, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

7:30-7:50 Panel Discussion / Q&A

Reception

7:50-9:30 p.m.

Thursday, June 25

Registration

7 a.m. - 7 p.m. | Grand Ballroom Foyer

Breakfast

7-8 a.m.

Workshop: AI in lymphoma: foundation models and beyond

7:15-7:45 a.m. | Grand Ballroom ABC

- Jansen Seheult, Mayo Clinic, Rochester, Minnesota, Minneapolis

Plenary Session 2: Next Generation Clinical Assessment

8-9:50 | Grand Ballroom ABC

Session Chair: David Scott, University of British Columbia, Vancouver, British Columbia, Canada

8-8:30 **Use of genetics to inform the diagnosis of rare B-cell lymphoma entities**
Davide Rossi, Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland

8:30-9 **Genetics to inform therapy in lymphoma**
Margaret Shipp, Dana Farber Cancer Institute, Boston, Massachusetts

9-9:30 **Integrating the microenvironment and omics into clinical workflows**
Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas

9:30-9:50 Panel Discussion / Q&A

Coffee Break

9:50-10:10 a.m. | Grand Ballroom Foyer

Plenary Session 3: The Lymphoma Microenvironment

10:10 a.m. -12 p.m. | Grand Ballroom ABC

Session Chair: Christian Steidl, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Advances in Malignant Lymphoma: From Discovery to Clinical Impact

in cooperation with the International Conference on Malignant Lymphoma (ICML)
June 24-27, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

10:10-10:40 **Tumor cell-microenvironment interplay in high risk DLBCL**
Anand D Jeyasekharan, Cancer Science Institute of Singapore, National University of Singapore, Singapore

10:40-11:10 **Using the microenvironment to predict response to therapy**
Justin Kline, University of Chicago, Chicago, Illinois

11:10-11:40 **Hodgkin lymphoma tumor microenvironment**
Christian Steidl, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

11:40-12 Panel Discussion / Q&A

Lunch on own
12-2 p.m.

Plenary Session 4: Spatial Analysis of Lymphoma
2-3:50 p.m. | Grand Ballroom ABC

Session Chair: Erin Parry, Dana Farber Cancer Institute, Boston, Massachusetts

2-2:30 **Dark zone lymphomas**
David Scott, University of British Columbia, Vancouver, British Columbia, Canada

2:30-3 **Transformation**
Erin Parry

3-3:30 **Decoding Lymphoma Morphology with Computer Vision: A Foundational Approach**
Jansen Seheult, Mayo Clinic, Rochester, Minnesota, Minneapolis

3:30-3:50 Panel Discussion / Q&A

Break
3:50-4:10

Spotlight on Proffered Abstracts

Session Chair: Michael Green, The University of Texas MD Anderson Cancer Center, Houston, TX
4:10-5:10 pm | Grand Ballroom ABC

4:10-4:15 **Cytokine-linked stromal remodeling in transformed follicular lymphoma impacts macrophage function and can be detected non-invasively**

Advances in Malignant Lymphoma: From Discovery to Clinical Impact

in cooperation with the International Conference on Malignant Lymphoma (ICML)
June 24-27, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

Laura Beckmann, Department of Medical Oncology, Dana-Farber Cancer Institute,
Boston, Massachusetts

- 4:16-4:21 **Bcl6-driven Cd70 -deficient Diffuse Large B-cell Lymphomas originate from innate-like cells with blunted CD4⁺ cytotoxic T-cell immune surveillance**
Elisa Mandato, Dana-Farber Cancer Institute, Boston, Massachusetts
- 4:21-4:27 **BTG1 mutation induces an age-associated B cell precursor population with extranodal and brain-infiltrating potential in diffuse large B cell lymphoma via interleukin-21 hypersensitivity**
Yulai Zhou, Yale University, New Haven, Connecticut
- 4:27-4:33 **BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trials**
Quinlan Sievers, Memorial Sloan Kettering, New York
- 4:34-4:40 **Mutant FOXO1 licenses MYC transformation of human germinal center B cells into dark-zone MYC-BCL2 high-grade B cell lymphomas**
Sabrina Giampaolo, The AIRC Institute of Molecular Oncology, Milano, Italy
- 4:41-4:47 **Mechanisms and impact of bystander killing by CAR T cells**
Joanna Chorazeczekowski, University of Chicago, Chicago, Illinois
- 4:47-4:53 **Spatially resolved microenvironment profiling reveals distinct follicular lymphoma archetypes**
Abe Yoshiaki, MD Anderson Cancer Center, Houston, Texas
- 4:54-5 **PKCδ-mediated feedback control of B-cell receptor signaling and its subversion in diffuse large B-cell lymphoma**
Ruifeng Sun, Yale University, New Haven, Connecticut

Poster session

5:15-7:15 pm | Grand Ballroom D

Friday, June 26

Registration

7 a.m. - 6:30 p.m. | Grand Ballroom Foyer

Breakfast

7-8 a.m.

Workshop: ctDNA analyses of lymphoid malignancies

7:15-7:45 a.m. | Grand Ballroom ABC

Advances in Malignant Lymphoma: From Discovery to Clinical Impact

in cooperation with the International Conference on Malignant Lymphoma (ICML)
June 24-27, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

- Mark Roschewski, Memorial Sloan Kettering Cancer Center, New York, New York

Plenary Session 5: New Targeted Therapeutic Strategies in Lymphoma

8-9:50 a.m. | Grand Ballroom ABC

Session Chair: Jason Westin, MD Anderson Cancer Center, Houston, Texas

- 8-8:30 **Targeting BTK in CLL and other B-cell malignancies: Continuous progress with a continuous therapy**
Kerry Rogers, Ohio State University, Columbus, Ohio
- 8:30-9 **Multitargeted combination strategies to cure patients with large B-cell lymphoma**
Mark Roschewski, Memorial Sloan Kettering Cancer Center, New York, New York
- 9-9:30 **Integrating novel agents into rational combinations**
Jason Westin
- 9:30-9:50 Panel Discussion / Q&A

Coffee Break

9:50-10:10 a.m. | Grand Ballroom Foyer

Plenary Session 6: Degraders in Lymphoma

10:10-12 p.m. | Grand Ballroom ABC

Session Chair: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Ticino, Switzerland

- 10:10-10:40 **Exploiting the E3 ligase FBXO21 as a novel therapeutic target and degrader in lymphoma**
Shannon Buckley, University of Utah, Salt Lake City, Utah
- 10:40-11:10 **Resistance to BTK degraders**
Francesco Bertoni
- 11:10-11:40 **The role of BTK degraders in CLL**
Justin Taylor, University of Miami Miller School of Medicine, Miami, Florida
- 11:40-12 Panel Discussion / Q&A

Lunch on own

Advances in Malignant Lymphoma: From Discovery to Clinical Impact

in cooperation with the International Conference on Malignant Lymphoma (ICML)
June 24-27, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

12-2 p.m.

Plenary Session 7: Rare Lymphomas

2-3:50 p.m. | Grand Ballroom ABC

Session Chair: Jean Koff, Winship Cancer Institute of Emory University, Atlanta, Georgia

2-2:30 **TP53-independent risk stratification in mantle cell lymphoma using a novel gene expression signature**
Jean Koff

2:30-3 **Navigating the landscape of peripheral T-cell lymphomas**
Teresa Palomero, Columbia University, New York, New York

3-3:30 **Updates on the treatment of Primary CNS Lymphoma**
Christian Grommes, Memorial Sloan Kettering Cancer Center, New York, New York, USA

3:30-3:50 Panel Discussion / Q&A

Coffee Break

3:50-4:10 p.m. | Grand Ballroom Foyer

Plenary Session 8: Advances in Cell Therapy

4:10-6:30 p.m. | Grand Ballroom ABC

Session Chair: Marcela Maus, Massachusetts General Hospital, Boston, Massachusetts

4:10-4:40 **Novel CAR-T cells in lymphoma**
Marcela Maus

4:40-5:10 **Armored CAR T cells**
Sarwish Rafiq, Winship Cancer Institute of Emory University, Atlanta, Georgia

5:10-5:40 **Analysis of site-specific CAR T cell efficacy in LBCL and development of novel engineering strategies**
Laura Evgin, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

5:40-6:10 **Emerging CAR T-Cell Toxicities and T-cell lymphomas after CAR T**
Premal Lulla, Baylor College of Medicine, Houston, Texas

6:10-6:30 **Panel Discussion / Q&A**

Advances in Malignant Lymphoma: From Discovery to Clinical Impact

in cooperation with the International Conference on Malignant Lymphoma (ICML)
June 24-27, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

Panelists:

Sarwish Rafiq, Winship Cancer Institute of Emory University, Atlanta, Georgia
Laura Evgin, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Premal Lulla, Baylor College of Medicine, Houston, Texas, United States
Marcela Maus, Massachusetts General Hospital, Boston, Massachusetts
Daniel Landsburg, University of Pennsylvania, Philadelphia, Pennsylvania
Jean Koff, Winship Cancer Institute of Emory University, Atlanta, GA

Saturday, June 27

Registration

7 a.m. - 1 p.m. | Grand Ballroom Foyer

Breakfast

7-8 a.m.

Workshop: Leveraging Spatial Technologies in Lymphoma

7:15-7:45 am | Grand Ballroom ABC

- Anand Jeyasekharan, Cancer Science Institute of Singapore, National University of Singapore, Singapore

Closing Keynote Lecture

8-9 am | Grand Ballroom ABC

8 a.m. Introduction of Keynote Speaker

Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY

8:10 a.m. Closing Keynote Lecture

Michel Nussenzweig, Rockefeller University, New York, New York

Plenary Session 9: The Origins of Lymphoma

Session Chair: Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY

9-10:50 a.m. | Grand Ballroom ABC

9-9:30 Cells of origin for lymphoma

Dinis Pedro Parente Calado, Francis Crick Institute, London, England, United Kingdom

Advances in Malignant Lymphoma: From Discovery to Clinical Impact

in cooperation with the International Conference on Malignant Lymphoma (ICML)

June 24-27, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

- 9:30-10 **Mouse models of mantle cell lymphoma**
Ron Jachimowicz, University Hospital Cologne, Germany
- 10-10:30 **At the crossroad of genetics and epigenetics: Mutational mechanisms
that remodel the epigenomic landscape**
Laura Pasqualucci, Columbia University, New York, New York
- 10:30-10:50 Panel Discussion / Q&A

Coffee Break

10:50-11:10 | Grand Ballroom Foyer

Plenary Session 10: Epigenetics

Session Chair: Michael Green, The University of Texas MD Anderson Cancer Center,
Houston, TX

11:10-12:30 p.m. | Grand Ballroom ABC

- 11:10-11:40 **Targeting the BCL6 transcription factor in lymphoma**
Michael Green
- 11:40-12:10 **Epigenetic regulation of the lymphoma microenvironment: from single-
cell behavioral reprogramming to systems-level niche corruption**
Wendy Beguelin, New York University, New York, New York
- 12:10-12:30 Panel Discussion / Q&A

Closing remarks

12:30 p.m.